Back to User profile » Mr Christopher Kiff
Paper published by Mr Christopher Kiff:
Original Research
![Noteworthy comment: This study assessed different methods to determine whether high ICERs (incremental cost-effectiveness ratio) are caused by high drug costs, high ‘background costs’ or a combination of both and how different approaches can alter the impact of background costs on the ICER where the marginal cost-effectiveness ratio is close to, or above, the cost-effectiveness threshold.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology
Retzler J, Davies H, Jenks M, Kiff C, Taylor M
ClinicoEconomics and Outcomes Research 2019, 11:309-324
Published Date: 3 May 2019